UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. _____________)*
FLEMINGTON PHARMACEUTICAL CORPORATION (Name of Issuer)
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE (Title of Class of Securities)
(Title of Class of Securities)
339280 10 9
(CUSIP Number)
NOVEMBER 12, 1997
(Date of Reportable Event)
This Schedule is filed pursuant to:
[ ] Rule 13d-1 (b)
[ ] Rule 13d-1 (c)
[X] Rule 13d-1 (d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13G
- -------------------------------------------------------------------------------
CUSIP NO. 339280 10 9
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Watson Pharmaceuticals, Inc.,
95-3872914
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
(b) /X/
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
a Nevada Corporation
- -------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 389,350
OWNED BY -------------------------------------------------
EACH 6 SHARED VOTING POWER
REPORTING 0
PERSON -------------------------------------------------
WITH 7 SOLE DISPOSITIVE POWER
389,350
-------------------------------------------------
8 SHARED DISPOSITIVE POWER
0
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
389,350
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* / /
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
10.0%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
ITEM 1 (A)-(B) Name of Issuer:
Flemington Pharmaceutical Corporation ("Issuer")
43 Emery Ave.
Flemington, New Jersey 08822
ITEM 2 (A)-(C) Name of Person Filing:
Watson Pharmaceuticals, Inc., a Nevada corporation ("Watson")
311 Bonnie Circle
Corona, CA 91720
ITEM 2 (D) Title of Class of Securities: common stock, $ .01 par
value ("Common Stock")
ITEM 2 (E) CUSIP Number: 339280 10 9
ITEM 3 Watson acquired 389,350 shares of the Issuer's Common Stock
through Watson's July 1995 acquisition of Circa
Pharmaceuticals, Inc. ("Circa"). Circa acquired the Common
Stock from the Issuer in November 1994, prior to the
Issuer's November 1997 Initial Public Offering. This
Schedule 13G is filed pursuant to Securities Exchange Act
rule 13d-1(d).
ITEM 4 Ownership:
The following information is provided as of December 31, 1997:
(a) Amount Beneficially Owned: 389,350 shares of Common Stock
(b) Percent of Class: 10.0%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 389,350
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition
of: 389,350
(iv) shared power to dispose or to direct the disposition
of: 0
ITEM 5 Ownership of Five Percent or Less of a Class: Not applicable
ITEM 6 Ownership of More than Five Percent on Behalf of
Another Person: Not applicable
ITEM 9 Notice of Dissolution of Group: Not applicable
ITEM 10 Certification: Not applicable
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
WATSON PHARMACEUTICALS, INC.
April 7, 1998
-----------------------------------
Date
/s/ ALLEN CHAO
-----------------------------------
Signature
Allen Chao, Ph.D., Chairman, President
and Chief Executive Officer
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL
CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).
